The REMIT (RE-irradiation of diffuse MIdline glioma paTients) study evaluates safety and the palliative efficacy of re-irradiation of patients with diffuse midline glioma (DMG). The study will introduce a standard re-irradiation treatment schedule for DMG patients who have progressed following primary treatment.
Diffuse midline glioma diagnosis: verified radiologically or histologically Biopsy is not mandatory for REMIT
Age ≥ 12 months to ≤21 years.
Min. 180 days/6 months have elapsed from the first day of the 1st RT course
1st course of radiotherapy
Presence of leptomeningeal spread or multifocal disease on MRI at progression
Other co-morbidity that according to the treating physician would impair participation in the study
>1 course of radiotherapy
Neurofibromatosis type 1
Rigshospitalet, Denmark
Lead sponsor
Aarhus University Hospital
Collaborator
Sahlgrenska University Hospital
Collaborator
Karolinska University Hospital
Collaborator
Radiumhospitalet, Oslo University Hospital
Collaborator